Suppr超能文献

液体活检中的外泌体微小RNA:前列腺癌的未来生物标志物

Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer.

作者信息

Valentino A, Reclusa P, Sirera R, Giallombardo M, Camps C, Pauwels P, Crispi S, Rolfo C

机构信息

Phase I-Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Belgium.

Center for Oncological Research (CORE), Antwerp University, Antwerp, Belgium.

出版信息

Clin Transl Oncol. 2017 Jun;19(6):651-657. doi: 10.1007/s12094-016-1599-5. Epub 2017 Jan 4.

Abstract

Prostate cancer is the second most diagnosed cancer in males in the world. Plasma quantification of prostate-specific antigen substantially improved the early detection of prostate cancer, but still lacks the required specificity. Clinical management of prostate cancer needs advances in the development of new non-invasive biomarkers, ameliorating current diagnosis and prognosis and guiding therapeutic decisions. microRNAs (miRNAs) are a class of small non-coding RNAs that regulate gene expression at the post-transcriptional level. These miRNAs are expressed in the cells and are also present in cell-derived extracellular vesicles such as exosomes. Exosomes have been shown to act as mediators for cell to cell communication because of the regulatory functions of their content. High levels of exosomes are found in several body fluids from cancer patients and could be a potential source of non-invasive biomarkers. In this review, we summarize the diagnostic and prognostic utility of exosomal miRNAs in prostate cancer.

摘要

前列腺癌是全球男性中第二大最常被诊断出的癌症。前列腺特异性抗原的血浆定量分析极大地改善了前列腺癌的早期检测,但仍缺乏所需的特异性。前列腺癌的临床管理需要在开发新的非侵入性生物标志物方面取得进展,以改善当前的诊断和预后并指导治疗决策。微小RNA(miRNA)是一类在转录后水平调节基因表达的小非编码RNA。这些miRNA在细胞中表达,也存在于细胞衍生的细胞外囊泡(如外泌体)中。由于其内容物的调节功能,外泌体已被证明可作为细胞间通讯的介质。在癌症患者的几种体液中发现了高水平的外泌体,它们可能是无创生物标志物的潜在来源。在本综述中,我们总结了外泌体miRNA在前列腺癌中的诊断和预后效用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验